Supernus to Participate in Annual Piper Sandler Healthcare Conference
11/18/2021 - 08:00 AM
ROCKVILLE, Md., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management will participate in a fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29 – December 2, 2021. The Company will also host investor meetings on Wednesday, December 1, 2021.
The pre-recorded fireside chat can be accessed beginning at 10:00 a.m. ET on November 22, 2021 by visiting Events & Presentations in the Investors section on the Company's website at www.supernus.com . An archived replay of this fireside chat will be available for 60 days on the Company's website after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression and rare CNS disorders.
For more information, please visit www.supernus.com .
CONTACTS:
Jack A. Khattar, President and CEO
or
INVESTOR CONTACT:
Supernus Pharmaceuticals Inc
SUPN Rankings
#3926 Ranked by Stock Gains
SUPN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Rockville
About SUPN
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
